Publications by authors named "H H GUNTHARD"
Late re-engagement into HIV care among adults in the Swiss HIV Cohort Study.
J Acquir Immune Defic Syndr
January 2025
Introduction: Little is known about the clinical status of persons with HIV (PWH) who re-engage in care after an interruption. We evaluated the immunological and clinical characteristics of individuals re-engaging in care within the Swiss HIV Cohort Study.
Methods: Participants who re-engaged in care after an interruption >14 months with a viral load ≥100 copies/mL were classified as having interrupted ART.
Background: Identifying risk factors for HIV rebound after treatment interruption is crucial for designing effective remission strategies.
Methods: Peripheral blood mononuclear cells from participants in the Zurich HIV Primary Infection Cohort (ZPHI, N=73) and ACTG study A5345 (N=44) were analyzed before ART interruption. We measured cell-associated HIV RNA, total HIV DNA, and proviral diversity (env gene).
Article Synopsis
- The study investigates how long-acting rilpivirine functions in real-life clinical settings, addressing gaps left by clinical trials on its pharmacokinetics in people with HIV.
- Researchers analyzed data from 238 patients to establish concentration curves and identify factors influencing drug exposure, finding differences in absorption rates between genders but minimal clinical impact.
- The findings suggest that around 50% of rilpivirine concentrations meet the optimal therapeutic threshold, indicating potential variability in treatment effectiveness among patients.
Article Synopsis
- - The text emphasizes that new antiretroviral drugs and formulations are continuously being developed for HIV prevention and treatment, highlighting the importance of updated strategies to manage the virus effectively.
- - A panel of expert physician scientists has compiled updated recommendations for 2024 based on extensive literature reviews and data from scientific conferences, focusing on treatment protocols tailored to specific patient needs.
- - Current recommendations advocate for antiretroviral therapy for all individuals with HIV, primarily using integrase strand transfer inhibitors, while also offering alternatives for those with unique circumstances, and suggesting both oral and injectable options for HIV prevention.
Background: Most individuals on combination antiretroviral therapy (ART) have HIV plasma viral loads below the limit of detection. However, episodes of low-level viremia (LLV) are observed in subsets of individuals, risk factors and clinical significance of which remain debated.
Methods: We included participants enrolled in the Swiss HIV Cohort Study, starting ART between July 1999 and April 2023, with HIV RNA <200 copies/ml six months post ART initiation.